Clinical Trials in Houston

Showing 4881-4900 of 13,620 trials

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

NCT04432857

This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.

Triple-negative Breast CancerNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the Bladder+2 more

Adlai Nortye Biopharma Co., Ltd.63 participantsStarted Aug 2020

St Louis, Missouri, United States • Houston, Texas, United States • Salt Lake City, Utah, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

NCT04919642

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

CholangiocarcinomaFGFR2 FusionFGFR2 Gene Mutation+2 more

TransThera Sciences (Nanjing), Inc.55 participantsStarted Dec 2021

Anchorage, Alaska, United States • Duarte, California, United States • Santa Monica, California, United States +29 more locations

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Find Trials by Condition in Houston

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

TRC-PAD Program: In-Clinic Trial-Ready Cohort

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Psychotherapy for PTSD Among Veterans Also Receiving Drug or Alcohol Treatment

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout